» Articles » PMID: 31798836

Utilising Artificial Intelligence to Determine Patients at Risk of a Rare Disease: Idiopathic Pulmonary Arterial Hypertension

Overview
Journal Pulm Circ
Publisher Wiley
Specialty Pulmonary Medicine
Date 2019 Dec 5
PMID 31798836
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Idiopathic pulmonary arterial hypertension is a rare and life-shortening condition often diagnosed at an advanced stage. Despite increased awareness, the delay to diagnosis remains unchanged. This study explores whether a predictive model based on healthcare resource utilisation can be used to screen large populations to identify patients at high risk of idiopathic pulmonary arterial hypertension. Hospital Episode Statistics from the National Health Service in England, providing close to full national coverage, were used as a measure of healthcare resource utilisation. Data for patients with idiopathic pulmonary arterial hypertension from the National Pulmonary Hypertension Service in Sheffield were linked to pre-diagnosis Hospital Episode Statistics records. A non-idiopathic pulmonary arterial hypertension control cohort was selected from the Hospital Episode Statistics population. Patient history was limited to ≤5 years pre-diagnosis. Information on demographics, timing/frequency of diagnoses, medical specialities visited and procedures undertaken was captured. For modelling, a bagged gradient boosting trees algorithm was used to discriminate between cohorts. Between 2008 and 2016, 709 patients with idiopathic pulmonary arterial hypertension were identified and compared with a stratified cohort of 2,812,458 patients classified as non-idiopathic pulmonary arterial hypertension with ≥1 ICD-10 coded diagnosis of relevance to idiopathic pulmonary arterial hypertension. A predictive model was developed and validated using cross-validation. The timing and frequency of the clinical speciality seen, secondary diagnoses and age were key variables driving the algorithm's performance. To identify the 100 patients at highest risk of idiopathic pulmonary arterial hypertension, 969 patients would need to be screened with a specificity of 99.99% and sensitivity of 14.10% based on a prevalence of 5.5/million. The positive predictive and negative predictive values were 10.32% and 99.99%, respectively. This study highlights the potential application of artificial intelligence to readily available real-world data to screen for rare diseases such as idiopathic pulmonary arterial hypertension. This algorithm could provide low-cost screening at a population level, facilitating earlier diagnosis, improved diagnostic rates and patient outcomes. Studies to further validate this approach are warranted.

Citing Articles

Assessing the precision of machine learning for diagnosing pulmonary arterial hypertension: a systematic review and meta-analysis of diagnostic accuracy studies.

Fadilah A, Putri V, Puling I, Willyanto S Front Cardiovasc Med. 2024; 11:1422327.

PMID: 39257851 PMC: 11385608. DOI: 10.3389/fcvm.2024.1422327.


Association of risk assessment at diagnosis with healthcare resource utilization and health-related quality of life outcomes in pulmonary arterial hypertension.

Lawrie A, Hamilton N, Wood S, Exposto F, Muzwidzwa R, Raiteri L Pulm Circ. 2024; 14(3):e12399.

PMID: 38979095 PMC: 11229026. DOI: 10.1002/pul2.12399.


An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension.

DuBrock H, Wagner T, Carlson K, Carpenter C, Awasthi S, Attia Z Eur Respir J. 2024; 64(1).

PMID: 38936966 PMC: 11269769. DOI: 10.1183/13993003.00192-2024.


Rare and complex diseases in focus: ChatGPT's role in improving diagnosis and treatment.

Zheng Y, Sun X, Feng B, Kang K, Yang Y, Zhao A Front Artif Intell. 2024; 7:1338433.

PMID: 38283995 PMC: 10808657. DOI: 10.3389/frai.2024.1338433.


Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service.

Kiely D, Hamilton N, Wood S, Durrington C, Exposto F, Muzwidzwa R BMJ Open. 2024; 14(1):e080068.

PMID: 38176861 PMC: 10773408. DOI: 10.1136/bmjopen-2023-080068.


References
1.
McGoon M, Benza R, Escribano-Subias P, Jiang X, Miller D, Peacock A . Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013; 62(25 Suppl):D51-9. DOI: 10.1016/j.jacc.2013.10.023. View

2.
Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

3.
Ashrafian H, Darzi A . Transforming health policy through machine learning. PLoS Med. 2018; 15(11):e1002692. PMC: 6233911. DOI: 10.1371/journal.pmed.1002692. View

4.
DAlonzo G, Barst R, Ayres S, Bergofsky E, Brundage B, Detre K . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5):343-9. DOI: 10.7326/0003-4819-115-5-343. View

5.
Lau E, Humbert M, Celermajer D . Early detection of pulmonary arterial hypertension. Nat Rev Cardiol. 2014; 12(3):143-55. DOI: 10.1038/nrcardio.2014.191. View